15 studies found for:    MK-3102
Show Display Options
Rank Status Study
1 Completed MK-3102 Phase III Clinical Trial - Placebo- and Sitagliptin-controlled Monotherapy Study in Japanese Participants With Type 2 Diabetes Mellitis (MK-3102-020)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to sitagliptin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: April 2014
2 Recruiting A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: November 2015
3 Active, not recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: January 2013
Primary Completion: March 2016
4 Recruiting A Study of the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028 AM1)
Condition: Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: May 2013
Primary Completion: March 2016
5 Active, not recruiting A Study to Assess the Safety and Efficacy of MK-3102 in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo to MK-3012;   Drug: Metformin;   Drug: Placebo to metformin;   Drug: Glimepiride
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: December 2012
Primary Completion: May 2015
6 Completed MK-3102 Phase III Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015 AM1)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Basal medication
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: May 2014
7 Active, not recruiting A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: MK-3102 Placebo;   Drug: Glimepiride;   Drug: Glimepiride Placebo;   Drug: Metformin;   Drug: Insulin Glargine
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: September 2012
Primary Completion: January 2015
8 Active, not recruiting Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Matching placebo to MK-3012;   Drug: Glimepiride;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: December 2014
9 Active, not recruiting Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Condition: Type 2 Diabetes
Interventions: Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to Sitagliptin;   Drug: Open-label Metformin;   Drug: Open-label Glimepiride
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: June 2013
Primary Completion: November 2014
10 Terminated A Study to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Glimepiride;   Drug: MK-3102 Placebo;   Drug: Glimepiride Placebo
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: July 2013
Primary Completion: April 2014
11 Recruiting A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: December 2017
12 Completed A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1[AM3])
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo;   Drug: pioglitazone;   Drug: metformin
Phase: Phase 2
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2010
Primary Completion: January 2012
13 Completed A Study of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes (3102-004)
Condition: Type 2 Diabetes (T2D)
Interventions: Drug: MK3102;   Drug: Comparator: Placebo
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: March 2010
Primary Completion: May 2010
14 Completed A Study of MK-3102 in Participants With Impaired Renal Function (MK-3102-009)
Conditions: Chronic Renal Insufficiency;   Type 2 Diabetes Mellitus
Intervention: Drug: MK-3102
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: August 2011
Primary Completion: March 2012
15 Completed A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: MK-3102
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: January 2013
Primary Completion: March 2013

Indicates status has not been verified in more than two years